Arbro Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Arbro Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $952.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Arbro Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $952.2K Trade | TransData Nexus

Arbro Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $952.2K Total Trade · DGFT Verified

Arbro Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $952.2K across 3 products in 2 therapeutic categories. Based on 68 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Trimethoprim ($536.1K), Norfloxacin ($377.7K), Aminophylline ($38.4K).

Arbro Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Arbro Pharmaceuticals Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Arbro Pharmaceuticals Private Limited? — Company Overview & Market Position

Arbro Pharmaceuticals Private Limited, established on June 28, 1985, is a privately held pharmaceutical company headquartered in New Delhi, India. The company operates under the Corporate Identification Number (CIN) U24232DL1985PTC021362 and is registered with the Registrar of Companies, Delhi. As of March 6, 2026, Arbro Pharmaceuticals has an authorized capital of ₹1.99 crore and a paid-up capital of ₹1.78 crore. The company employs approximately 369 professionals, reflecting its commitment to quality and innovation in the pharmaceutical sector. Arbro Pharmaceuticals specializes in the manufacturing and export of pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories.

What Does Arbro Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Trimethoprim$536.1K 2Norfloxacin$377.7K

Product Portfolio — Top 3 by Export Value

Arbro Pharmaceuticals Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Trimethoprim	Advanced Antibiotics	$536.1K	22	2.0%	11
2	Norfloxacin	Advanced Antibiotics	$377.7K	41	4.6%	5
3	Aminophylline	Respiratory & OTC	$38.4K	5	0.7%	13

Arbro Pharmaceuticals Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $952.2K. The top category is Advanced Antibiotics (96.0% of portfolio), followed by Respiratory & OTC (4.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Arbro Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Arbro Pharmaceuticals operates state-of-the-art manufacturing facilities in New Delhi, adhering to WHO-GMP standards. These facilities are equipped to produce a diverse range of pharmaceutical formulations, including tablets, capsules, dry syrups, oral powders, and oral liquids, catering to both human and veterinary segments. The company's manufacturing capabilities are complemented by its research and development (R&D) division, which focuses on product innovation and technology upgradation, thereby strengthening its position in the pharmaceutical industry.

3Key Leadership

The leadership team at Arbro Pharmaceuticals is headed by Managing Director Mr. Vijay Kumar Arora, who has been instrumental in the company's growth since its inception. Dr. Saurabh Arora serves as the Director, contributing to the company's strategic direction and expansion. Mr. Sunil Kumar Jaitly holds the position of Whole-Time Director, overseeing daily operations and ensuring compliance with industry standards. This leadership trio brings a wealth of experience and vision, driving Arbro Pharmaceuticals towards continued success in the global pharmaceutical market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Arbro Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Arbro Pharmaceuticals has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully submitted numerous dossiers for regulatory approvals in these regions, demonstrating its commitment to meeting international standards. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, Arbro's proactive approach to regulatory affairs indicates a strategic focus on compliance and market access in these key markets.

2Emerging Markets

Arbro Pharmaceuticals has strategically positioned itself in emerging markets across Africa, Latin America, and Southeast Asia. The company's dedication to providing high-quality, cost-effective medicines aligns with the healthcare needs of these regions. Arbro's WHO-GMP certified facilities and commitment to regulatory compliance enhance its credibility and facilitate market entry in these areas. The company's focus on product innovation and technology upgradation further strengthens its position in these emerging markets.

3Geographic Strategy

Arbro Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Arbro Pharmaceuticals' FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's proactive approach to regulatory affairs, including the submission of numerous dossiers for regulatory approvals in various countries, suggests a commitment to meeting international standards. While the absence of publicly disclosed FDA approvals may limit immediate market access in the U.S., Arbro's focus on compliance and quality positions it well for future opportunities in this market.

2WHO & EU GMP

Arbro Pharmaceuticals' manufacturing facilities are WHO-GMP certified, ensuring adherence to international quality standards. The company's commitment to quality is further demonstrated by its ISO 9001:2008 certification, reflecting a robust quality management system. While specific details regarding EU GMP certificates and EDQM status are not publicly disclosed, Arbro's WHO-GMP certification and ISO accreditation indicate a strong foundation in quality manufacturing practices.

3CDSCO & Indian Regulatory

Arbro Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Arbro Pharmaceuticals operates in a competitive landscape, focusing on therapeutic areas such as Advanced Antibiotics and Respiratory & OTC products. The company's export portfolio, valued at $952,000 USD across 68 shipments, is concentrated in these two categories, with Advanced Antibiotics comprising 96.0% and Respiratory & OTC products 4.0%. This concentration indicates a strategic focus on high-demand therapeutic areas. While specific market share data for competitors in these categories is not publicly available, Arbro's emphasis on quality manufacturing and regulatory compliance positions it as a strong player in these segments.

2Key Differentiators

Arbro Pharmaceuticals' key differentiators include its commitment to quality, as evidenced by its WHO-GMP certification and ISO 9001:2008 accreditation. The company's diversified product portfolio, encompassing over 700 formulations across various therapeutic segments, demonstrates its capacity for innovation and adaptability. Arbro's integrated approach, combining manufacturing, R&D, and regulatory compliance, enables it to deliver comprehensive solutions to its clients. Additionally, the company's strategic focus on emerging markets reflects its proactive approach to growth and market diversification.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Arbro Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Arbro Pharmaceuticals has a track record of consistent export activity, with a total export value of $952,000 USD across 68 shipments. The company's portfolio is concentrated in two therapeutic categories: Advanced Antibiotics (96.0%) and Respiratory & OTC products (4.0%). This concentration indicates a strategic focus on high-demand therapeutic areas. Arbro's commitment to quality is demonstrated by its WHO-GMP certification and ISO 9001:2008 accreditation, reflecting adherence to international manufacturing standards. The company's proactive approach to regulatory affairs, including the submission of numerous dossiers for approvals in various countries, suggests reliability and a commitment to compliance.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

WHO-GMP Certification: Confirms adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO website or by contacting Arbro Pharmaceuticals directly.

ISO 9001:2008 Certification: Indicates a robust quality management system. Verification can be done through the International Organization for Standardization (ISO) website or by contacting Arbro Pharmaceuticals directly.

Frequently Asked Questions — Arbro Pharmaceuticals Private Limited

How many pharmaceutical products does Arbro Pharmaceuticals Private Limited export from India?

Arbro Pharmaceuticals Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Trimethoprim ($536.1K), Norfloxacin ($377.7K), Aminophylline ($38.4K). Total export value is $952.2K.

What is Arbro Pharmaceuticals Private Limited's total pharmaceutical export value?

Arbro Pharmaceuticals Private Limited's total pharmaceutical export value is $952.2K, based on 68 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Arbro Pharmaceuticals Private Limited cover?

Arbro Pharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Advanced Antibiotics (96.0%, 2 products), Respiratory & OTC (4.0%, 1 products).

Get Full Arbro Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.